Marco S.
- Country
- Italy
- Department
- Hematology Department
Research Overview
- Randomized European Trial of Autologous Transplantation with Rituximab, Ibrutinib, and Ara-C Induction in Generalized Mantle Cell Lymphoma
- Evaluation of Itolizumab and Corticosteroids for Initial Management of Acute Graft Versus Host Disease in a Phase 3 Randomized Controlled Trial
- Phase 2 Study of Ruxolitinib with Brentuximab Vedotin or Pembrolizumab in Relapsed/Refractory Classical Hodgkin Lymphoma
Data & Insights
Has run more than one trial at 29 of 177 partner sites.
Specializations
Lymphoma Treatment
The investigator specializes in treating complex cases of classical Hodgkin lymphoma (cHL), particularly focusing on patients with relapsed or refractory conditions. Their research explores innovative combination therapies involving JAK1/2 inhibitors and targeted immunotherapy approaches.
- Refractory Hodgkin Lymphoma Management
- Combination Immunotherapy Strategies
- Advanced Treatment Protocols
Mantle Cell Lymphoma
The investigator conducts research in generalized mantle cell lymphoma treatment, exploring innovative therapeutic combinations. Their work includes evaluation of autologous stem cell transplantation protocols and maintenance therapy strategies using targeted agents.
- Novel Therapeutic Combinations
- Transplantation Protocols
- Maintenance Therapy Approaches
Transplant Complications
The investigator studies treatment approaches for acute Graft Versus Host Disease, a significant complication following bone marrow transplants. Their research focuses on novel biological therapies in combination with conventional treatments for managing transplant-related complications.
- GVHD Management Strategies
- Corticosteroid Combination Therapy
- Post-Transplant Care
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.